Solo educación · requiere revisión profesional
Liraglutide · First-generation GLP-1 agonist, FDA-approved
The daily GLP-1 medicine that preceded semaglutide — now available as a generic.
Revisado médicamente por Bernard Garcia, MD
Qué es
Liraglutide is a once-daily GLP-1 receptor agonist approved as Victoza (type 2 diabetes, 2010) and Saxenda (chronic weight management, 2014). Generic versions began to reach the US market in 2024–2025, which matters for cost.
Cómo funciona
Same class as semaglutide, with a shorter half-life requiring daily injection and, in trials, smaller average weight reduction than the weekly agents. Side-effect profile is similar, dominated by nausea.
Estado de la investigación
| Área de investigación | Estado |
|---|---|
| Type 2 diabetes | FDA-approved (Victoza) · generics available |
| Chronic weight management | FDA-approved (Saxenda) |
| Adolescent obesity (12+) | FDA-approved label (Saxenda) |
| Head-to-head with weekly agents | Smaller average effect in trials |
El estado refleja únicamente el contexto de la investigación publicada y no constituye una afirmación de seguridad, eficacia o idoneidad para ninguna persona.
¿Es legal?
Liraglutide is FDA-approved under its brand names, with generics now available. Prescription-only. This is a general note, not legal advice.
Preguntas frecuentes
Why would anyone use a daily injection instead of a weekly one?
Cost and availability, mainly. Generic liraglutide is considerably cheaper. A provider weighs that against effect size and tolerability.
Is it a peptide?
Yes — an acylated GLP-1 analogue peptide.
Is it available compounded?
With generics available, compounded copies are generally not permitted. Ask a provider.
Siguiente paso
Siguiente paso: una consulta confidencial de 3 minutos, revisada por un profesional con licencia. No se promete ni se da a entender ningún tratamiento.
Gratis · unos 10 minutos · revisado por un médico con licencia
Educación general · No es consejo médico · Se requiere aprobación profesional